Chartbook: Medicaid Pharmacy Benefit Use and Reimbursement in 2005

June 2009

Ann Bagchi
James Verdier
Dominick Esposito

Submitted to:
U.S. Department of Health and Human Services
Centers for Medicare & Medicaid Services
Office of Research, Development, and Information
7500 Security Boulevard
Baltimore, MD 21244

Submitted by:
Mathematica Policy Research, Inc.
P.O. Box 2393
Princeton, NJ 08543-2393
Telephone: (609) 799-3535
Facsimile: (609) 799-0005

Project Officer:
David Baugh

Project Director:
James Verdier
INTRODUCTION AND OVERVIEW

This chartbook, prepared for the Centers for Medicare & Medicaid Services (CMS) by Mathematica Policy Research, Inc., presents highlights and key comparisons from the Statistical Compendium on Medicaid pharmacy benefit use and reimbursement in 2005. The 54 exhibits in the chartbook are summarized below.

Beneficiary Characteristics and Illustrative Use and Reimbursement Measures

Exhibit 1: Distribution of Medicaid Study Population Beneficiary Characteristics
Exhibit 2: Illustrative Measures for Medicaid Study Population Pharmacy Benefit Use and Reimbursement

Study Population Characteristics

Exhibit 3: Distribution of Medicaid Study Population by Age Group, Nondual and Dual Eligible Beneficiaries
Exhibit 4: Distribution of Medicaid Study Population by Disability Status, Nondual and Dual Eligible Beneficiaries
Exhibit 5: Distribution of Medicaid Study Population by Race, Nondual and Dual Eligible Beneficiaries

Medicaid Pharmacy Reimbursement and Use, by Type of Beneficiary

Exhibit 6: Average Monthly Medicaid Pharmacy Reimbursement, by Age Group
Exhibit 7: Distribution of Medicaid Age Groups and Total Pharmacy Reimbursement
Exhibit 8: Average Monthly Medicaid Pharmacy Reimbursement, by Basis of Eligibility and Dual Status
Exhibit 9: Percentage of Medicaid Beneficiaries with at Least One Prescription Drug Claim, by Dual Eligibility Status
Exhibit 10: Average Annual Number of Medicaid Prescription Drug Claims per Beneficiary, by Dual Eligibility Status
Exhibit 11: Number of Medicaid Prescriptions per Benefit Month, by Basis of Eligibility and Dual Eligibility Status
Exhibit 12: Average Annual Medicaid Prescription Drug Spending per Beneficiary, by Dual Eligibility Status
Exhibit 13: Distribution of Medicaid Dual Eligibility Status and Total Pharmacy Reimbursement

Medicaid Pharmacy Use and Reimbursement, Nondual Beneficiaries

Exhibit 14: Distribution of Medicaid Beneficiaries and Total Pharmacy Reimbursement among Nondual Beneficiaries, by Basis of Eligibility
Exhibit 15: Total Annual Medicaid Reimbursement for Top 10 Drug Groups among Nondual Beneficiaries
Exhibit 16: Percentage of Medicaid Pharmacy Reimbursement and Users for Top 10 Drug Groups among Nondual Beneficiaries
Exhibit 17: Percentage of Medicaid Pharmacy Reimbursement and Users for Top 7 Therapeutic Categories among Nondual Beneficiaries
Exhibit 18: Average Monthly Medicaid Pharmacy Reimbursement among Nondual Beneficiaries, by State
Medicaid Pharmacy Use and Reimbursement, Dual Eligible Beneficiaries

Exhibit 19: Generic Prescriptions as Percentage of All Medicaid Prescriptions among Nondual Beneficiaries, by State
Exhibit 20: Distribution of Medicaid Beneficiaries and Total Pharmacy Reimbursement among Dual Eligibles, by Basis of Eligibility
Exhibit 21: Total Annual Medicaid Reimbursement for Top 10 Drug Groups among Dual Eligibles
Exhibit 22: Percentage of Medicaid Pharmacy Reimbursement and Users for Top 10 Drug Groups Among Dual Eligibles
Exhibit 23: Percentage of Medicaid Pharmacy Reimbursement and Users for Top 7 Therapeutic Categories among Dual Eligibles
Exhibit 24: Distribution of Annual Medicaid Pharmacy Reimbursement for Dual Eligibles, Under-Age-65 Disabled vs. Age 65 and Older
Exhibit 25: Average Monthly Medicaid Pharmacy Reimbursement among Dual Eligibles, by Beneficiary Nursing Facility Residence
Exhibit 26: Average Monthly Medicaid Pharmacy Reimbursement among Dual Eligibles, by State
Exhibit 27: Generic Prescriptions as a Percentage of All Medicaid Prescriptions among Dual Eligibles, by State
Exhibit 28: Average Annual Medicaid Pharmacy Reimbursement Amount per Beneficiary for Aged Dual Eligibles, by State
Exhibit 29: Average Annual Medicaid Pharmacy Reimbursement Amount per Beneficiary for Under-Age-65 Disabled Dual Eligible Beneficiaries, by State
Exhibit 30: Average Annual Medicaid Pharmacy Reimbursement Amount per Beneficiary for Dual Eligible All-Year Nursing Facility Residents, by State

Medicaid Pharmacy Use and Reimbursement, Drugs Excluded by Statute from Medicare Part D

Exhibit 31: Percentage of Medicaid Beneficiaries Using at Least One Drug Excluded from Medicare Part D
Exhibit 32: Annual Medicaid Pharmacy Reimbursement Per User for Drugs Excluded from Medicare Part D, Nondual and Dual Eligible Beneficiaries
Exhibit 33: Annual Medicaid Pharmacy Reimbursement for Drugs Excluded from Medicare Part D for Nondual and Dual Eligible Beneficiaries as a Percentage of Total Annual Medicaid Reimbursement for Nondual and Dual Eligible Beneficiaries


Overview
By Basis of Eligibility

Nondual Beneficiaries

Dual Eligible Beneficiaries
BENEFICIARY CHARACTERISTICS AND ILLUSTRATIVE USE AND REIMBURSEMENT MEASURES
### EXHIBIT 1
DISTRIBUTION OF MEDICAID STUDY POPULATION
BENEFICIARY CHARACTERISTICS, 2005

<table>
<thead>
<tr>
<th>Beneficiary Characteristics</th>
<th>Among All Medicaid Beneficiaries&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Among Nondual Beneficiaries&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Among Dual Eligibles&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Among Beneficiaries Who Resided in Nursing Facilities All Year&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 and younger</td>
<td>21</td>
<td>25</td>
<td>&lt; 1</td>
<td></td>
</tr>
<tr>
<td>6–14</td>
<td>20</td>
<td>24</td>
<td>&lt; 1</td>
<td></td>
</tr>
<tr>
<td>15–20</td>
<td>12</td>
<td>15</td>
<td>&lt; 1</td>
<td></td>
</tr>
<tr>
<td>21–44</td>
<td>25</td>
<td>27</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>45–64</td>
<td>10</td>
<td>8</td>
<td>22</td>
<td>15&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>65–74</td>
<td>5</td>
<td>&lt; 1</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>75–84</td>
<td>4</td>
<td>&lt; 1</td>
<td>23</td>
<td>30</td>
</tr>
<tr>
<td>85 and older</td>
<td>3</td>
<td>&lt; 1</td>
<td>15</td>
<td>43</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>40</td>
<td>40</td>
<td>37</td>
<td>29</td>
</tr>
<tr>
<td>Female</td>
<td>60</td>
<td>59</td>
<td>63</td>
<td>71</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>23</td>
<td>24</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>White</td>
<td>45</td>
<td>43</td>
<td>58</td>
<td>75</td>
</tr>
<tr>
<td>Other/Unknown</td>
<td>32</td>
<td>33</td>
<td>23</td>
<td>11</td>
</tr>
<tr>
<td><strong>Dual Eligibility Status&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual Eligibles</td>
<td>16</td>
<td>0</td>
<td>100</td>
<td>91</td>
</tr>
<tr>
<td>Nondual Beneficiaries</td>
<td>84</td>
<td>100</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td><strong>Basis of Eligibility&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td>49</td>
<td>58</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>Adults</td>
<td>24</td>
<td>29</td>
<td>1</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>Disabled</td>
<td>17</td>
<td>12</td>
<td>43</td>
<td>18</td>
</tr>
<tr>
<td>Aged</td>
<td>10</td>
<td>1</td>
<td>56</td>
<td>82</td>
</tr>
<tr>
<td><strong>Number of Beneficiaries in Study Population</strong></td>
<td>42,599,571</td>
<td>35,581,286</td>
<td>7,018,285</td>
<td>865,173</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This table is based on information contained in Tables 2, ND.2, D.2, ND.8, and D.8 in the Statistical Compendium Volume, United States (hereafter “the Compendium”).

<sup>a</sup>Medicaid beneficiaries featured in this chartbook include those who had fee-for-service (FFS) Medicaid pharmacy benefit coverage for at least one month during calendar year 2005. Beneficiaries who were in capitated managed care arrangements for the entire year are excluded. For more details on how we determined the study population, see Table 1 of the Compendium.

<sup>b</sup>Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefit coverage for at least one month during their Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never
dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefit coverage. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

This group includes beneficiaries who resided in nursing facilities throughout their Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined all-year nursing facility residency.

Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children’s group includes children receiving foster care and adoptive services.

The percentage represents all ages below 65.
EXHIBIT 2

ILLUSTRATIVE MEASURES OF MEDICAID STUDY POPULATION PHARMACY BENEFIT USE AND REIMBURSEMENT, 2005\textsuperscript{a}

<table>
<thead>
<tr>
<th>Measures of Pharmacy Benefit Use and Reimbursement</th>
<th>Among All Medicaid Beneficiaries\textsuperscript{b}</th>
<th>Among Nondual Beneficiaries\textsuperscript{b}</th>
<th>Among Dual Eligibles\textsuperscript{b}</th>
<th>Among Beneficiaries Who Resided in Nursing Facilities All Year\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Medicaid Pharmacy Reimbursement (in $ million)</td>
<td>$40,187</td>
<td>$18,333</td>
<td>$21,854</td>
<td>$3,436</td>
</tr>
<tr>
<td>Average Annual Pharmacy Reimbursement per Beneficiary\textsuperscript{c}</td>
<td>$943</td>
<td>$515</td>
<td>$3,114</td>
<td>$3,971</td>
</tr>
<tr>
<td>Average Pharmacy Reimbursement per Benefit Month\textsuperscript{d}</td>
<td>$114</td>
<td>$66</td>
<td>$295</td>
<td>$392</td>
</tr>
<tr>
<td>Average Annual Number of Prescriptions per Beneficiary</td>
<td>13.5</td>
<td>7.3</td>
<td>45.2</td>
<td>69.9</td>
</tr>
<tr>
<td>Average Number of Prescriptions per Benefit Month</td>
<td>1.6</td>
<td>0.9</td>
<td>4.3</td>
<td>6.9</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This table is based on information contained in Tables 3, 4, 6, ND.3, ND.4, ND.6, ND.8, ND.9, D.3, D.4, D.6, D.8, D.9, and N.1a in the Compendium.

\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}See footnotes to Exhibit 1 for how these groups were defined. Annual or monthly measures reflect use and reimbursement among beneficiaries in FFS settings, and may thus be higher or lower than if use and reimbursement in capitated managed care settings were included.

\textsuperscript{c}Annual per-beneficiary use and reimbursement include all use and reimbursement during the year for the number of months of Medicaid FFS pharmacy benefit coverage. Thus, some beneficiaries may have had only one month of coverage, while others were covered for twelve months. Medicaid beneficiaries in the study population had, on average, 8.3 months of coverage. The comparable number was 7.8 months among nondual beneficiaries and 10.6 months among dual eligible beneficiaries, and 10.1 months among beneficiaries who resided in nursing facilities throughout their Medicaid enrollment in 2005.

\textsuperscript{d}Monthly use and reimbursement amounts were calculated by dividing total use and reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
STUDY POPULATION CHARACTERISTICS
EXHIBIT 3

DISTRIBUTION OF MEDICAID STUDY POPULATION BY AGE GROUP, NONDUAL AND DUAL ELIGIBLE BENEFICIARIES, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.2 and D.2 of the Compendium.

*Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 4

DISTRIBUTION OF MEDICAID STUDY POPULATION BY DISABILITY STATUS, NONDUAL AND DUAL ELIGIBLE BENEFICIARIES, 2005a,b

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.2 and D.2 of the Compendium.

*aDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

*bThe disabled eligibility group includes beneficiaries of any age who were determined to be eligible for Medicaid because of disability or blindness.
EXHIBIT 5

DISTRIBUTION OF MEDICAID STUDY POPULATION BY RACE, NONDUAL AND DUAL ELIGIBLE BENEFICIARIES, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.2 and D.2 of the Compendium.

*Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
MEDICAID PHARMACY REIMBURSEMENT AND USE,
BY TYPE OF BENEFICIARY
EXHIBIT 6

AVERAGE MONTHLY MEDICAID PHARMACY REIMBURSEMENT, BY AGE GROUP, 2005\textsuperscript{a,b}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Exhibit6.png}
\caption{Average monthly Medicaid pharmacy reimbursement by age group, 2005\textsuperscript{a,b}.}
\end{figure}

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table 4 of the Compendium.

\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 7

DISTRIBUTION OF MEDICAID AGE GROUPS AND TOTAL PHARMACY REIMBURSEMENT, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables 2, 3, and 6 of the Compendium.

aThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.
EXHIBIT 8

AVERAGE MONTHLY MEDICAID PHARMACY REIMBURSEMENT, 
BY BASIS OF ELIGIBILITY AND DUAL STATUS, 2005\textsuperscript{a,b,c,d}

<table>
<thead>
<tr>
<th>Eligibility Status</th>
<th>Dual Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>$295</td>
</tr>
<tr>
<td>Children</td>
<td>$66</td>
</tr>
<tr>
<td>Adults</td>
<td>$45</td>
</tr>
<tr>
<td>Disabled</td>
<td>$240</td>
</tr>
<tr>
<td>Aged</td>
<td>$295</td>
</tr>
<tr>
<td>Nondual Beneficiaries</td>
<td>$114</td>
</tr>
<tr>
<td>Dual Eligibles</td>
<td>$25</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables 4, ND.4, and D.4 of the Compendium.

\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.

\textsuperscript{c}Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

\textsuperscript{d}Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 9

PERCENTAGE OF MEDICAID BENEFICIARIES WITH AT LEAST ONE PRESCRIPTION DRUG CLAIM,
BY DUAL ELIGIBILITY STATUS, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.3 and D.3 of the Compendium.

*aDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 10

AVERAGE ANNUAL NUMBER OF MEDICAID PRESCRIPTION DRUG CLAIMS PER BENEFICIARY, BY DUAL ELIGIBILITY STATUS, 2005\textsuperscript{a,b}

<table>
<thead>
<tr>
<th></th>
<th>Nondual Beneficiaries</th>
<th>Dual Eligibles</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7.3</td>
<td>45.2</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.3 and D.3 of the Compendium.

\textsuperscript{a} Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

\textsuperscript{b} Nondual beneficiaries, on average, had fewer months of Medicaid eligibility in 2005 than dual eligible beneficiaries: 7.8 months for nonduals and 10.5 months for duals.
EXHIBIT 11
NUMBER OF MEDICAID PRESCRIPTIONS PER BENEFIT MONTH, BY BASIS OF ELIGIBILITY AND DUAL ELIGIBILITY STATUS, 2005$^{a,b}$

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.4 and D.4 of the Compendium.

$^a$Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

$^b$Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 12

AVERAGE ANNUAL MEDICAID PRESCRIPTION DRUG SPENDING PER BENEFICIARY,
BY DUAL ELIGIBILITY STATUS, 2005a,b

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.3 and D.3 of the Compendium.

aDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

bNonduals, on average, had fewer months of Medicaid eligibility in 2005 than dual eligible beneficiaries: 7.8 months for nonduals and 10.6 months for duals.
EXHIBIT 13

DISTRIBUTION OF MEDICAID DUAL ELIGIBILITY STATUS AND TOTAL PHARMACY REIMBURSEMENT, 2005\textsuperscript{a,b}

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables 2, ND.2, D.2, 6, ND.6, and D.6 of the Compendium.

\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
MEDICAID PHARMACY USE AND REIMBURSEMENT,
NONDUAL BENEFICIARIES
Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.2, ND.3, and ND.6 of the Compendium.

- The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

- Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

- Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
The top 10 drug groups (out of over 90 drug groups) accounted for 57 percent of total Medicaid FFS pharmacy reimbursement for nondual beneficiaries in 2005.

($ million)

- Antipsychotics: $2,466
- Antiasthmatic: $1,273
- Anticonvulsant: $1,221
- Antiviral: $1,139
- Antidepressants: $1,020
- Ulcer Drugs: $867
- Stimulants/Anti-obesity/Anorexiants: $689
- Analgesics - Narcotic: $667
- Antidiabetic: $613
- Antihyperlipidemic: $610

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table ND.7 of the Compendium.

aThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

bAnnual per-beneficiary reimbursement includes all reimbursement during the year for the number of months of Medicaid FFS pharmacy benefit coverage. Thus, some beneficiaries may have had only one month of coverage, while others were covered for twelve months. At the national level, nondual eligible Medicaid beneficiaries in the study population had, on average, 7.8 months of coverage.

cThe top 10 drug groups were determined based on total Medicaid reimbursement in 2005. For information about these drug groups, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

dDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 16
PERCENTAGE OF MEDICAID PHARMACY REIMBURSEMENT AND USERS FOR TOP 10 DRUG GROUPS AMONG NONDUAL BENEFICIARIES, 2005\textsuperscript{a,b,c,d}

<table>
<thead>
<tr>
<th>Drug Group</th>
<th>Percent of Nondual Beneficiary Pharmacy Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotics</td>
<td>13%</td>
</tr>
<tr>
<td>Antiasthmatic</td>
<td>18%</td>
</tr>
<tr>
<td>Anticonvulsant</td>
<td>7%</td>
</tr>
<tr>
<td>Antiviral</td>
<td>5%</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>2%</td>
</tr>
<tr>
<td>Ulcer Drugs</td>
<td>6%</td>
</tr>
<tr>
<td>Stimulants/Anti-obesity/Anorexiants</td>
<td>10%</td>
</tr>
<tr>
<td>Analgesics - Narcotic</td>
<td>8%</td>
</tr>
<tr>
<td>Antidiabetic</td>
<td>4%</td>
</tr>
<tr>
<td>Antihyperlipidemic</td>
<td>3%</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table ND.7 of the Compendium.

\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. For information about these drug groups, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

\textsuperscript{c}The top 10 drugs groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

\textsuperscript{d}Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 17

PERCENTAGE OF PHARMACY MEDICAID REIMBURSEMENT AND USERS FOR TOP 7 THERAPEUTIC CATEGORIES
AMONG NONDUAL BENEFICIARIES, 2005\textsuperscript{a,b,c,d}

The top 7 therapeutic categories (out of 18 therapeutic categories) accounted for 74 percent of total Medicaid FFS pharmacy reimbursement for nondual beneficiaries in 2005.

\begin{itemize}
  \item \textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.
  \item \textsuperscript{b}A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).
  \item \textsuperscript{c}Top 7 categories were determined based on total Medicaid reimbursement in 2005. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).
  \item \textsuperscript{d}Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
\end{itemize}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{chart.png}
\caption{Percent of Nondual Beneficiary Pharmacy Reimbursement by Therapeutic Category}
\end{figure}

\textbf{Source:} Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table ND.6 of the Compendium.
EXHIBIT 18

AVERAGE MONTHLY MEDICAID PHARMACY REIMBURSEMENT AMONG NONDUAL BENEFICIARIES, BY STATE, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table N.2 of the Compendium for the nation. The Compendium was prepared for 48 states (excluding Arizona and Maine) and the District of Columbia. FFS pharmacy reimbursement information is not available for Arizona due to a very high share of beneficiary enrollment in prepaid managed care plans.

The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.

Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 19
GENERIC PRESCRIPTIONS AS PERCENTAGE OF ALL MEDICAID PRESCRIPTIONS
AMONG NONDUAL BENEFICIARIES, BY STATE, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table N.2 of the Compendium for the nation. The Compendium was prepared for 48 states (excluding Arizona and Maine) and the District of Columbia. FFS pharmacy reimbursement information is not available for Arizona due to a very high share of beneficiary enrollment in prepaid managed care plans.

aBrand-name drugs, sometimes called “innovator single-source drugs,” are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called “innovator multiple-source drugs,” are brand-name drugs whose patents have expired. Generic drugs, sometimes called “non-innovator multiple-source drugs,” are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

bDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
MEDICAID PHARMACY USE AND REIMBURSEMENT,
DUAL ELIGIBLE BENEFICIARIES
EXHIBIT 20

DISTRIBUTION OF MEDICAID BENEFICIARIES AND TOTAL PHARMACY REIMBURSEMENT AMONG DUAL ELIGIBLES, BY BASIS OF ELIGIBILITY, 2005\(^{a,b,c,d}\)

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables D.2, D.3, and D.6 of the Compendium.

\(^{a}\)Children and adults comprise less than 1 percent each of dual eligible beneficiaries both in percentage of beneficiaries and in percentage of pharmacy reimbursement.

\(^{b}\)The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\(^{c}\)Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

\(^{d}\)Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 21

TOTAL ANNUAL MEDICAID REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG DUAL ELIGIBLES, 2005\textsuperscript{A,B,C,D}

The top 10 drug groups (out of over 90 drug groups) accounted for 61 percent of total Medicaid FFS pharmacy reimbursement for dual eligibles in 2005.

<table>
<thead>
<tr>
<th>Drug Group</th>
<th>Reimbursement ($ million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotic</td>
<td>$2,902</td>
</tr>
<tr>
<td>Antihyperlipidemic</td>
<td>$1,626</td>
</tr>
<tr>
<td>Ulcer Drugs</td>
<td>$1,554</td>
</tr>
<tr>
<td>Anticonvulsant</td>
<td>$1,255</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>$1,238</td>
</tr>
<tr>
<td>Antidiabetic</td>
<td>$1,199</td>
</tr>
<tr>
<td>Analgesics - Narcotic</td>
<td>$923</td>
</tr>
<tr>
<td>Antihypertensive</td>
<td>$917</td>
</tr>
<tr>
<td>Antihypertensive</td>
<td>$894</td>
</tr>
<tr>
<td>Antiviral</td>
<td>$838</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table D.7 of the Compendium.

\textsuperscript{A}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{B}Annual per-beneficiary reimbursement includes all reimbursement during the year for the number of months of Medicaid FFS pharmacy benefit coverage. Thus, some beneficiaries may have had only one month of coverage, while others were covered for twelve months. At the national level, dual eligible Medicaid beneficiaries in the study population had, on average, 10.6 months of coverage.

\textsuperscript{C}The top 10 drug groups were determined based on total Medicaid reimbursement in 2005. For information about these drug groups, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

\textsuperscript{D}Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 22

PERCENTAGE OF MEDICAID PHARMACY REIMBURSEMENT AND USERS FOR TOP 10 DRUG GROUPS AMONG DUAL ELIGIBLES, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table D.7 of the Compendium.

The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. For information about these drug groups, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

The top 10 drugs groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

The top 7 therapeutic categories (out of 18 therapeutic categories) accounted for 77 percent of total Medicaid FFS pharmacy reimbursement for dual beneficiaries in 2005. Top 7 categories were determined based on total Medicaid reimbursement in 2005. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table D.6 of the Compendium.

EXHIBIT 23
PERCENTAGE OF MEDICAID PHARMACY REIMBURSEMENT AND USERS FOR TOP 7 THERAPEUTIC CATEGORIES AMONG DUAL ELIGIBLES, 2005

The top 7 therapeutic categories (out of 18 therapeutic categories) accounted for 77 percent of total Medicaid FFS pharmacy reimbursement for dual beneficiaries in 2005.

<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Percent of Dual Eligible Pharmacy Reimbursement</th>
<th>Percent of Dual Eligible Beneficiaries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Nervous System Drugs</td>
<td>21%</td>
<td>49%</td>
</tr>
<tr>
<td>Cardiovascular Agents</td>
<td>18%</td>
<td>64%</td>
</tr>
<tr>
<td>Gastrointestinal Agents</td>
<td>9%</td>
<td>41%</td>
</tr>
<tr>
<td>Endocrine/Metabolic Drugs</td>
<td>8%</td>
<td>44%</td>
</tr>
<tr>
<td>Analgesics and Anesthetics</td>
<td>8%</td>
<td>50%</td>
</tr>
<tr>
<td>Neromuscular Agents</td>
<td>7%</td>
<td>28%</td>
</tr>
<tr>
<td>Anti-infective Agents</td>
<td>7%</td>
<td>52%</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table D.6 of the Compendium.

aThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

bA user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

cTop 7 categories were determined based on total Medicaid reimbursement in 2005. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

dDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 24

DISTRIBUTION OF ANNUAL MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLES, UNDER-AGE-65 DISABLED VS. AGE 65 AND OLDER, 2005\textsuperscript{a,b,c}

<table>
<thead>
<tr>
<th>Percent of Beneficiaries</th>
<th>Percent of Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disabled Dual Eligibles</td>
<td></td>
</tr>
<tr>
<td>Under Age 65</td>
<td></td>
</tr>
<tr>
<td>$10,000 and more</td>
<td>11%</td>
</tr>
<tr>
<td>$5,001 to $10,000</td>
<td>38%</td>
</tr>
<tr>
<td>$1,000 to $5,000</td>
<td>35%</td>
</tr>
<tr>
<td>$0 to $1,000</td>
<td>17%</td>
</tr>
</tbody>
</table>

| Dual Eligibles            |                         |
| Age 65 and Older          |                         |
| $10,000 and more          | 3%                      |
| $5,001 to $10,000         | 14%                     |
| $1,000 to $5,000          | 35%                     |
| $0 to $1,000              | 38%                     |

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Supplemental Tables 1A and 1B of the Compendium for the nation.

\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}Annual per-beneficiary reimbursement includes all reimbursement during the year for the number of months of Medicaid FFS pharmacy benefit coverage. Thus, some beneficiaries may have had only one month of coverage, while others were covered for twelve months. At the national level, dual eligible Medicaid beneficiaries in the study population had, on average, 10.6 months of coverage in 2005.

\textsuperscript{c}Dual eligibles include beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefit coverage during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 25

AVERAGE MONTHLY MEDICAID PHARMACY REIMBURSEMENT AMONG DUAL ELIGIBLES, BY BENEFICIARY NURSING FACILITY RESIDENCE, 2005\(^{A,B,C}\)

<table>
<thead>
<tr>
<th>Category</th>
<th>Reimbursement Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Duals</td>
<td>$295</td>
</tr>
<tr>
<td>Dual All-Year NF Residents</td>
<td>$377</td>
</tr>
<tr>
<td>Dual Part-Year NF Residents</td>
<td>$342</td>
</tr>
<tr>
<td>Dual With No NF Use</td>
<td>$281</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table D.4 of the Compendium.

\(^{a}\)The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\(^{b}\)Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.

\(^{c}\)Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

**EXHIBIT 26**

**AVERAGE MONTHLY MEDICAID PHARMACY REIMBURSEMENT AMONG DUAL ELIGIBLES, BY STATE, 2005**

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table N.5 of the Compendium for the nation. The Compendium was prepared for 48 states (excluding Arizona and Maine) and the District of Columbia. FFS pharmacy reimbursement information is not available for Arizona due to a very high share of beneficiary enrollment in prepaid managed care plans.

a The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

b Monthly use and reimbursement amounts were calculated by dividing the total use and reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.

c Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 27

GENERIC PRESCRIPTIONS AS A PERCENTAGE OF ALL MEDICAID PRESCRIPTIONS AMONG DUAL ELIGIBLES, BY STATE, 2005

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Table N.5 of the Compendium for the nation. The Compendium was prepared for 48 states (excluding Arizona and Maine) and the District of Columbia. FFS pharmacy reimbursement information is not available for Arizona due to a very high share of beneficiary enrollment in prepaid managed care plans.

aBrand-name drugs, sometimes called “innovator single-source drugs,” are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called “innovator multiple-source drugs,” are brand-name drugs whose patents have expired. Generic drugs, sometimes called “non-innovator multiple-source drugs,” are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

bDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 28

AVERAGE ANNUAL MEDICAID PHARMACY REIMBURSEMENT AMOUNT PER BENEFICIARY FOR AGED DUAL ELIGIBLES, BY STATE, 2005\textsuperscript{A,B,C}

<table>
<thead>
<tr>
<th>State</th>
<th>Reimbursement Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM</td>
<td>$966</td>
</tr>
<tr>
<td>LA</td>
<td>$1,327</td>
</tr>
<tr>
<td>NJ</td>
<td>$1,454</td>
</tr>
<tr>
<td>NV</td>
<td>$1,510</td>
</tr>
<tr>
<td>NC</td>
<td>$1,607</td>
</tr>
<tr>
<td>MS</td>
<td>$1,725</td>
</tr>
<tr>
<td>NY</td>
<td>$1,970</td>
</tr>
<tr>
<td>ND</td>
<td>$2,165</td>
</tr>
<tr>
<td>OH</td>
<td>$2,291</td>
</tr>
<tr>
<td>WI</td>
<td>$2,400</td>
</tr>
<tr>
<td>CO</td>
<td>$2,534</td>
</tr>
<tr>
<td>CA</td>
<td>$2,663</td>
</tr>
<tr>
<td>TX</td>
<td>$2,781</td>
</tr>
<tr>
<td>GA</td>
<td>$2,903</td>
</tr>
<tr>
<td>MA</td>
<td>$3,012</td>
</tr>
<tr>
<td>MI</td>
<td>$3,124</td>
</tr>
<tr>
<td>FL</td>
<td>$3,297</td>
</tr>
<tr>
<td>HI</td>
<td>$3,400</td>
</tr>
<tr>
<td>WI</td>
<td>$3,438</td>
</tr>
<tr>
<td>MI</td>
<td>$3,458</td>
</tr>
<tr>
<td>OH</td>
<td>$3,547</td>
</tr>
<tr>
<td>FL</td>
<td>$3,619</td>
</tr>
<tr>
<td>IA</td>
<td>$3,725</td>
</tr>
<tr>
<td>MN</td>
<td>$3,800</td>
</tr>
<tr>
<td>WI</td>
<td>$3,890</td>
</tr>
<tr>
<td>WI</td>
<td>$3,895</td>
</tr>
<tr>
<td>WI</td>
<td>$3,900</td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in State Tables D.3 of the Compendium. The Compendium was prepared for 48 states (excluding Arizona and Maine) and the District of Columbia. FFS pharmacy reimbursement information is not available for Arizona due to a very high share of beneficiary enrollment in prepaid managed care plans.

\textsuperscript{A}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{B}Annual per-beneficiary reimbursement includes all reimbursement during the year for the number of months of Medicaid FFS pharmacy benefit coverage. Thus, some beneficiaries may have had only one month of coverage, while others were covered for twelve months. At the national level, aged dual eligible Medicaid beneficiaries in the study population had, on average, 10.3 months of coverage.

\textsuperscript{C}Dual eligibles include beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefit coverage during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
AVERAGE ANNUAL MEDICAID PHARMACY REIMBURSEMENT AMOUNT PER BENEFICIARY FOR UNDER-AGE-65 DISABLED DUAL ELIGIBLE BENEFICIARIES, BY STATE, 2005\textsuperscript{a,b,c}

<table>
<thead>
<tr>
<th>State</th>
<th>Reimbursement Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>$469</td>
<td></td>
</tr>
<tr>
<td>$600</td>
<td></td>
</tr>
<tr>
<td>$1,100</td>
<td></td>
</tr>
<tr>
<td>$1,600</td>
<td></td>
</tr>
<tr>
<td>$2,100</td>
<td></td>
</tr>
<tr>
<td>$2,600</td>
<td></td>
</tr>
<tr>
<td>$3,100</td>
<td></td>
</tr>
<tr>
<td>$3,600</td>
<td></td>
</tr>
<tr>
<td>$4,100</td>
<td></td>
</tr>
<tr>
<td>$4,600</td>
<td></td>
</tr>
<tr>
<td>$5,100</td>
<td></td>
</tr>
<tr>
<td>$5,600</td>
<td></td>
</tr>
<tr>
<td>$6,100</td>
<td></td>
</tr>
</tbody>
</table>

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in State Tables D.3 of the Compendium. The Compendium was prepared for 48 states (excluding Arizona and Maine) and the District of Columbia. FFS pharmacy reimbursement information is not available for Arizona due to a very high share of beneficiary enrollment in prepaid managed care plans.

\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}Annual per-beneficiary reimbursement includes all reimbursement during the year for the number of months of Medicaid FFS pharmacy benefit coverage. Thus, some beneficiaries may have had only one month of coverage, while others were covered for twelve months. At the national level, disabled dual eligible Medicaid beneficiaries in the study population had, on average, 10.9 months of coverage.

\textsuperscript{c}Dual eligibles include beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefit coverage during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 30

AVERAGE ANNUAL MEDICAID PHARMACY REIMBURSEMENT AMOUNT PER BENEFICIARY FOR DUAL ELIGIBLE ALL-YEAR NURSING FACILITY RESIDENTS, BY STATE, 2005\(^a,b,c\)

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in State Tables D.3 of the Compendium. The Compendium was prepared for 48 states (excluding Arizona and Maine) and the District of Columbia. FFS pharmacy reimbursement information is not available for Arizona due to a very high share of beneficiary enrollment in prepaid managed care plans.

\(^a\)The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\(^b\)Annual per-beneficiary reimbursement includes all reimbursement during the year for the number of months of Medicaid FFS pharmacy benefit coverage. Thus, some beneficiaries may have had only one month of coverage, while others were covered for twelve months. At the national level, dual eligible Medicaid beneficiaries in the study population who resided in nursing facilities full-year had, on average, 10.1 months of coverage.

\(^c\)Dual eligibles include beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefit coverage during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
MEDICAID PHARMACY USE AND REIMBURSEMENT,
DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
EXHIBIT 31

PERCENTAGE OF MEDICAID BENEFICIARIES USING AT LEAST ONE DRUG EXCLUDED FROM MEDICARE PART D, 2005<sup>a,b</sup>

<table>
<thead>
<tr>
<th>Nondual Beneficiaries</th>
<th>Dual Eligibles</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>35,581,286</strong></td>
<td><strong>7,018,285</strong></td>
</tr>
</tbody>
</table>

- **At Least 1 Drug Excluded from Part D**
  - Nondual Beneficiaries: 27%
  - Dual Eligibles: 56%

- **No Drugs Excluded from Part D**
  - Nondual Beneficiaries: 73%
  - Dual Eligibles: 44%

Source: Medicaid Analytic Extract (MAX), 2005. These graphs are based on the information contained in Tables ND.11 and D.11 of the Compendium.

<sup>a</sup>The statute that established the Medicare Part D drug benefit excluded several types of drugs from Part D coverage. State Medicaid programs are required to continue covering these drugs for dual eligibles if they are covered for any other Medicaid beneficiaries. Drugs excluded from the Medicare Part D drug benefit include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

<sup>b</sup>Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 32

ANNUAL MEDICAID PHARMACY REIMBURSEMENT PER USER FOR DRUGS EXCLUDED FROM MEDICARE PART D, NONDUAL AND DUAL ELIGIBLE BENEFICIARIES, 2005\textsuperscript{a,b}

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.13 and D.13 of the Compendium.

\textsuperscript{a}The statute that established the Medicare Part D drug benefit excluded several types of drugs from Part D coverage. State Medicaid programs are required to continue covering these drugs for dual eligibles if they are covered for any other Medicaid beneficiaries. Drugs excluded from the Medicare Part D drug benefit include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

\textsuperscript{b}Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 33

ANNUAL MEDICAID PHARMACY REIMBURSEMENT FOR DRUGS EXCLUDED FROM MEDICARE PART D FOR NONDUAL AND DUAL ELIGIBLE BENEFICIARIES AS A PERCENTAGE OF TOTAL ANNUAL MEDICAID REIMBURSEMENT FOR NONDUAL AND DUAL ELIGIBLE BENEFICIARIES, 2005\(^a,b\)

Source: Medicaid Analytic Extract (MAX), 2005. This graph is based on the information contained in Tables ND.13 and D.13 of the Compendium.

\(^a\)The statute that established the Medicare Part D drug benefit excluded several types of drugs from Part D coverage. State Medicaid programs are required to continue covering these drugs for dual eligibles if they are covered for any other Medicaid beneficiaries. Drugs excluded from the Medicare Part D drug benefit include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

\(^b\)Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
MEDICAID PHARMACY USE AND REIMBURSEMENT,
EXHIBIT 34


aThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

bMonthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 35

MEDICAID PHARMACY REIMBURSEMENT AS A PERCENTAGE OF COSTS OF ALL SERVICES,


\textsuperscript{a}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{b}Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.

\textsuperscript{c}In seven states in 2004 (DE, IA, NE, NY, TX, UT, and WV) and 8 states in 2005 (DE, IA, IL, NE, NY, TX, UT, and WV), expenditures include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. In NV, managed care plans provided a pharmacy benefit only to dual eligibles and not nondual beneficiaries. As a result, pharmacy reimbursement as a percentage of the costs of all Medicaid services is higher in 2004 and 2005 than they would otherwise be.
EXHIBIT 36


![Bar Chart]


aDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

bThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

cMonthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 37


Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 38


<table>
<thead>
<tr>
<th>Year</th>
<th>Nondual Beneficiaries</th>
<th>Dual Eligibles</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>55%</td>
<td>84%</td>
</tr>
<tr>
<td>2001</td>
<td>52%</td>
<td>86%</td>
</tr>
<tr>
<td>2002</td>
<td>53%</td>
<td>85%</td>
</tr>
<tr>
<td>2003</td>
<td>56%</td>
<td>84%</td>
</tr>
<tr>
<td>2004</td>
<td>56%</td>
<td>86%</td>
</tr>
<tr>
<td>2005</td>
<td>56%</td>
<td>86%</td>
</tr>
</tbody>
</table>


Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 39


Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 40


aBrand-name drugs, sometimes called “innovator single-source drugs,” are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called “innovator multiple-source drugs,” are brand-name drugs whose patents have expired. Generic drugs, sometimes called “non-innovator multiple-source drugs,” are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, [http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615] (October 26 2007).

aMedicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
EXHIBIT 42

AVERAGE MONTHLY MEDICAID PHARMACY REIMBURSEMENT BY BASIS OF ELIGIBILITY,


aThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

bMonthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.

cMedicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
EXHIBIT 43


\textsuperscript{a}Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

\textsuperscript{b}Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 44


aMedicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

bNondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 45


\textsuperscript{a}Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

\textsuperscript{b}Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

\textsuperscript{c}The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

\textsuperscript{d}Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 46


Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

Nondual beneficiaries include beneficiaries who were never dually eligible or were dually eligible but never had Medicaid FFS pharmacy benefits. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 47


<table>
<thead>
<tr>
<th></th>
<th>1999</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Beneficiaries</td>
<td>5.3</td>
<td>5.7</td>
<td>6.2</td>
<td>6.9</td>
<td>7.0</td>
<td>6.2</td>
</tr>
<tr>
<td>Aged</td>
<td>3.1</td>
<td>3.2</td>
<td>3.4</td>
<td>3.8</td>
<td>3.9</td>
<td>3.9</td>
</tr>
<tr>
<td>Disabled</td>
<td>2.2</td>
<td>2.5</td>
<td>2.8</td>
<td>2.9</td>
<td>3.0</td>
<td>3.0</td>
</tr>
</tbody>
</table>


<sup>a</sup>Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

<sup>b</sup>Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table I in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 48


aMedicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

bDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

<table>
<thead>
<tr>
<th>Year</th>
<th>Aged</th>
<th>Disabled</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>$1,350</td>
<td>$2,030</td>
</tr>
<tr>
<td>2001</td>
<td>$1,834</td>
<td>$2,698</td>
</tr>
<tr>
<td>2002</td>
<td>$1,994</td>
<td>$2,885</td>
</tr>
<tr>
<td>2003</td>
<td>$2,138</td>
<td>$3,362</td>
</tr>
<tr>
<td>2004</td>
<td>$2,420</td>
<td>$3,731</td>
</tr>
<tr>
<td>2005</td>
<td>$2,534</td>
<td>$3,886</td>
</tr>
</tbody>
</table>


- **Medicaid basis of eligibility is classified as:** aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

- **Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.**

- **The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.**

- **Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.**
EXHIBIT 50


aMedicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness, and thus includes a large number of dual eligibles. The children’s group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

bDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

cThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

dMonthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 51

AVERAGE ANNUAL MEDICAID DRUG REIMBURSEMENT AMONG DUAL ELIGIBLE BENEFICIARIES


aDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

bThe Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

cMonthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.
EXHIBIT 52


*Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
EXHIBIT 53


<table>
<thead>
<tr>
<th>Year</th>
<th>All Duals</th>
<th>Full-Year Nursing Facility Residents</th>
<th>Under-Age-65 Disabled Duals</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>5.3</td>
<td>0.8</td>
<td>2.2</td>
</tr>
<tr>
<td>2001</td>
<td>5.7</td>
<td>0.9</td>
<td>2.5</td>
</tr>
<tr>
<td>2002</td>
<td>6.2</td>
<td>0.9</td>
<td>2.8</td>
</tr>
<tr>
<td>2003</td>
<td>6.7</td>
<td>0.8</td>
<td>2.9</td>
</tr>
<tr>
<td>2004</td>
<td>6.9</td>
<td>0.8</td>
<td>3.0</td>
</tr>
<tr>
<td>2005</td>
<td>7.0</td>
<td>0.8</td>
<td>3.0</td>
</tr>
</tbody>
</table>


aDual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.
The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.


a Dual eligibles are beneficiaries who had Medicare as well as Medicaid FFS pharmacy benefits during any month of Medicaid enrollment in 2005. Refer to Table 1 in the Compendium for more information about how we determined dual eligibility status.

b The Medicaid pharmacy reimbursement amount is the amount Medicaid reimbursed pharmacies, including dispensing fees minus beneficiary copayment. Reimbursement amounts are gross amounts prior to the receipt of rebates from drug manufacturers to states.

c Monthly reimbursement amounts were calculated by dividing the total reimbursement among all beneficiaries in the study population by the total number of benefit months of those beneficiaries. Benefit months are months during which beneficiaries had FFS pharmacy benefit coverage.